Cargando…
Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use
BACKGROUND: Desmoid‐type fibromatosis (DTF) has a highly variable clinical course with varying intensity of symptoms. The objectives of this study were to identify subgroups of DTF patients based on physical symptom burden and to compare symptom burden subgroups on health‐related quality of life (HR...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315709/ https://www.ncbi.nlm.nih.gov/pubmed/37119048 http://dx.doi.org/10.1002/cam4.5985 |
_version_ | 1785067554975252480 |
---|---|
author | Schut, Anne‐Rose W. de Bruin, Leanne E. de Rooij, Belle H. Lidington, Emma Timbergen, Milea J. M. van der Graaf, Winette T. A. van Houdt, Winan J. Bonenkamp, Johannes J. Jones, Robin L. Grünhagen, Dirk. J. Sleijfer, Stefan Gennatas, Spyridon Verhoef, Cornelis Husson, Olga |
author_facet | Schut, Anne‐Rose W. de Bruin, Leanne E. de Rooij, Belle H. Lidington, Emma Timbergen, Milea J. M. van der Graaf, Winette T. A. van Houdt, Winan J. Bonenkamp, Johannes J. Jones, Robin L. Grünhagen, Dirk. J. Sleijfer, Stefan Gennatas, Spyridon Verhoef, Cornelis Husson, Olga |
author_sort | Schut, Anne‐Rose W. |
collection | PubMed |
description | BACKGROUND: Desmoid‐type fibromatosis (DTF) has a highly variable clinical course with varying intensity of symptoms. The objectives of this study were to identify subgroups of DTF patients based on physical symptom burden and to compare symptom burden subgroups on health‐related quality of life (HRQoL) and healthcare use (univariate and multivariate). METHODS: Desmoid‐type fibromatosis patients from the United Kingdom and the Netherlands received cross‐sectional questionnaires on HRQoL (EORTC QLQ‐C30), DTF‐specific HRQoL (DTF‐QoL) and healthcare utilisation. Latent class cluster analysis was performed to identify subgroups based on patients' symptom burden using EORTC QLQ‐C30 and DTF‐QoL physical symptom items. Multivariate linear and logistic regression analyses were conducted to examine associations of symptom burden with HRQoL and healthcare utilisation, respectively. RESULTS: Among 235 DTF patients, four symptom burden clusters were identified, with low symptom burden (24%), intermediate symptom burden‐low pain (20%), intermediate symptom burden‐high pain (25%) and high symptom burden (31%). DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001) and reported more general and DTF‐related visits to their general practitioner compared to the low symptom burden cluster (p < 0.01). In the multivariate analyses, symptom burden was independently associated with both HRQoL and healthcare utilisation. CONCLUSIONS: This study identified four distinct subgroups of DTF patients based on their level of symptom burden, with a considerable number of patients being highly symptomatic. Knowledge of the level of symptom burden DTF patients experience can help to identify patients at risk of poorer outcomes and tailor supportive care to the individual needs of DTF patients. |
format | Online Article Text |
id | pubmed-10315709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103157092023-07-04 Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use Schut, Anne‐Rose W. de Bruin, Leanne E. de Rooij, Belle H. Lidington, Emma Timbergen, Milea J. M. van der Graaf, Winette T. A. van Houdt, Winan J. Bonenkamp, Johannes J. Jones, Robin L. Grünhagen, Dirk. J. Sleijfer, Stefan Gennatas, Spyridon Verhoef, Cornelis Husson, Olga Cancer Med RESEARCH ARTICLES BACKGROUND: Desmoid‐type fibromatosis (DTF) has a highly variable clinical course with varying intensity of symptoms. The objectives of this study were to identify subgroups of DTF patients based on physical symptom burden and to compare symptom burden subgroups on health‐related quality of life (HRQoL) and healthcare use (univariate and multivariate). METHODS: Desmoid‐type fibromatosis patients from the United Kingdom and the Netherlands received cross‐sectional questionnaires on HRQoL (EORTC QLQ‐C30), DTF‐specific HRQoL (DTF‐QoL) and healthcare utilisation. Latent class cluster analysis was performed to identify subgroups based on patients' symptom burden using EORTC QLQ‐C30 and DTF‐QoL physical symptom items. Multivariate linear and logistic regression analyses were conducted to examine associations of symptom burden with HRQoL and healthcare utilisation, respectively. RESULTS: Among 235 DTF patients, four symptom burden clusters were identified, with low symptom burden (24%), intermediate symptom burden‐low pain (20%), intermediate symptom burden‐high pain (25%) and high symptom burden (31%). DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001) and reported more general and DTF‐related visits to their general practitioner compared to the low symptom burden cluster (p < 0.01). In the multivariate analyses, symptom burden was independently associated with both HRQoL and healthcare utilisation. CONCLUSIONS: This study identified four distinct subgroups of DTF patients based on their level of symptom burden, with a considerable number of patients being highly symptomatic. Knowledge of the level of symptom burden DTF patients experience can help to identify patients at risk of poorer outcomes and tailor supportive care to the individual needs of DTF patients. John Wiley and Sons Inc. 2023-04-29 /pmc/articles/PMC10315709/ /pubmed/37119048 http://dx.doi.org/10.1002/cam4.5985 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Schut, Anne‐Rose W. de Bruin, Leanne E. de Rooij, Belle H. Lidington, Emma Timbergen, Milea J. M. van der Graaf, Winette T. A. van Houdt, Winan J. Bonenkamp, Johannes J. Jones, Robin L. Grünhagen, Dirk. J. Sleijfer, Stefan Gennatas, Spyridon Verhoef, Cornelis Husson, Olga Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use |
title | Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use |
title_full | Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use |
title_fullStr | Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use |
title_full_unstemmed | Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use |
title_short | Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use |
title_sort | physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315709/ https://www.ncbi.nlm.nih.gov/pubmed/37119048 http://dx.doi.org/10.1002/cam4.5985 |
work_keys_str_mv | AT schutannerosew physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT debruinleannee physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT derooijbelleh physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT lidingtonemma physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT timbergenmileajm physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT vandergraafwinetteta physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT vanhoudtwinanj physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT bonenkampjohannesj physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT jonesrobinl physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT grunhagendirkj physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT sleijferstefan physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT gennatasspyridon physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT verhoefcornelis physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse AT hussonolga physicalsymptomburdeninpatientswithdesmoidtypefibromatosisanditsimpactonhealthrelatedqualityoflifeandhealthcareuse |